Balchem Corporation — Q1 2015 Form 10-Q
Reporting period: Three months ended March 31, 2015. Unaudited consolidated financial statements; dollar amounts below are in millions unless noted. Balchem develops and sells specialty ingredients and products for food, nutrition, pharmaceutical, animal health, industrial and medical-device sterilization markets.
Financial performance
- Revenue: $144.9, up 68.5% from $86.0. The May 2014 SensoryEffects acquisition was the primary driver: its acquired business contributed $54.5 of Q1 sales. The prior-year comparison predates the acquisition and is therefore not directly comparable.
- Profit and margins: Gross profit was $43.1, with gross margin of 29.8% versus 27.0%. Operating income was $25.0, up 87.5%, and operating margin was 17.3% versus 15.5%. Net earnings were $15.2, up 70.6%; diluted EPS was $0.48 versus $0.29. Effective tax rate was 34.3% versus 33.5%.
- Segment sales: SensoryEffects $67.8 versus $12.2; Animal Nutrition & Health $42.7 versus $40.9; Industrial Products $20.8 versus $20.2; Specialty Products $13.6 versus $12.8. Segment earnings were $7.7, $8.5, $3.1 and $5.7, respectively. SensoryEffects’ acquired product lines had lower gross margins, while Animal Nutrition & Health benefited from lower raw-material costs, improved mix and higher-volume efficiencies.
- Cash flow and investment: Operating cash flow was $26.6 versus $10.2. Capital expenditures were $6.4; investing cash outflow was $6.8. Financing cash outflow was $12.3, including $8.8 of debt principal payments and $9.3 of dividends. Cash increased $6.3 to $56.6.
- Liquidity: Working capital was $101.0 versus $85.8 at year-end 2014. Cash included $10.9 held by foreign subsidiaries that management intends to permanently reinvest abroad; repatriation for U.S. needs could incur additional U.S. taxes.
- Debt: Total debt was $323.8, including $35.0 current and $288.8 long-term, compared with $332.5 at December 31, 2014. The company had $100.0 available on its revolving facility, a 1.67% borrowing rate at quarter-end, and was compliant with quarterly covenants. A 100-basis-point rate change would affect annual interest expense and cash flow by approximately $3.2.
Material changes, outlook and risks
- Management reorganized reporting into four segments—Specialty Products, SensoryEffects, Animal Nutrition & Health, and Industrial Products—and retrospectively revised certain prior-period segment and intangible-asset information. The change did not affect consolidated net income or cash flows.
- Operating expense increased to $18.1 from $9.9, primarily due to $5.5 of additional acquired-intangible amortization; Q1 2014 included $1.3 of acquisition and joint-venture-related professional costs. Interest expense rose to $1.9, primarily because of acquisition financing.
- Management expects operating cash flow to fund working capital, capital investment and debt service, and continues to pursue acquisition candidates. The filing provides no quantified earnings or revenue guidance and cautions that quarterly results are not necessarily indicative of full-year results.
- Risks include floating-rate debt, foreign-currency and raw-material price exposure, and market sensitivities in animal nutrition (including dairy economics), commodity choline and shale-fracking applications. Management says it manages exposures where possible through pricing and operations; it does not use derivatives for hedging or trading.
- Environmental matters include ongoing discussions with New York regulators about a former drum-remediation site and a Superfund site at the Verona facility. Management believes other litigation, claims and assessments will not materially affect financial position, results or liquidity. No material changes to the risk factors in the 2014 Form 10-K were reported.
Key facts for investors to verify
- How much future growth and margin performance depends on SensoryEffects, given acquisition-driven year-over-year comparisons and the acquired products’ lower gross margins.
- Debt repayment capacity, covenant headroom, floating-rate exposure and plans for the $100.0 revolving facility.
- Whether operating cash flow, capital spending and dividends remain sustainable as integration and investment continue.
- Foreign-subsidiary cash treatment and potential tax cost if funds are repatriated.
- Updates on environmental matters and the integration of SensoryEffects into internal controls; the company expected to include the acquired business in its year-end 2015 controls assessment.